Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Enhancement by tetrahydrouridine of 1-beta-D-arabinofuranosylcytosine (cytarabine) oral activity in L1210 leukemic mice.

× No keyword cloud information.

14 in total

1. Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.

Authors: Jan H Beumer; Julie L Eiseman; Judith A Gilbert; Julianne L Holleran; Archibong E Yellow-Duke; Dana M Clausen; David Z D'Argenio; Matthew M Ames; Pamela A Hershberger; Robert A Parise; Lihua Bai; Joseph M Covey; Merrill J Egorin
Journal: Cancer Chemother Pharmacol Date: 2010-05-05 Impact factor: 3.333

Review 2. Pharmacokinetic drug interactions of commonly used anticancer drugs.

Authors: F M Balis
Journal: Clin Pharmacokinet Date: 1986 May-Jun Impact factor: 6.447

3. Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models.

Authors: H S Chen; J F Gross
Journal: J Pharmacokinet Biopharm Date: 1979-02

Review 4. Antineoplastic and immunosuppressive drugs. I. Biochemical and clinical pharmacological considerations.

Authors: A H Chalmers; L A Burgoyne; A W Murray
Journal: Drugs Date: 1972 Impact factor: 9.546

5. Phosphorylation of 5-bromodeoxycytidine in cells infected with herpes simplex virus.

Authors: G M Cooper
Journal: Proc Natl Acad Sci U S A Date: 1973-12 Impact factor: 11.205

6. Capacity of deoxycytidine to selectively antagonize cytotoxicity of 5-halogenated analogs of deoxycytidine without loss of antiherpetic activity.

Authors: L M Fox; J A Mekras; C B Bagwell; S B Greer
Journal: Antimicrob Agents Chemother Date: 1982-09 Impact factor: 5.191

7. Induction of deoxycytidine deaminase activity in mammalian cell lines by infection with herpes simplex virus type 1.

Authors: T S Chan
Journal: Proc Natl Acad Sci U S A Date: 1977-04 Impact factor: 11.205

8. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.

Authors: Reda Z Mahfouz; Ania Jankowska; Quteba Ebrahem; Xiaorong Gu; Valeria Visconte; Ali Tabarroki; Pramod Terse; Joseph Covey; Kenneth Chan; Yonghua Ling; Kory J Engelke; Mikkael A Sekeres; Ramon Tiu; Jaroslaw Maciejewski; Tomas Radivoyevitch; Yogen Saunthararajah
Journal: Clin Cancer Res Date: 2013-01-03 Impact factor: 12.531

9. Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice.

Authors: Jan H Beumer; Julie L Eiseman; Robert A Parise; Jeffry A Florian; Erin Joseph; David Z D'Argenio; Robert S Parker; Brittany Kay; Joseph M Covey; Merrill J Egorin
Journal: Cancer Chemother Pharmacol Date: 2007-11-15 Impact factor: 3.333

10. Differences in deoxycytidine metabolism in mouse and rat.

Authors: T S Chan; B D Lakhchaura; T F Hsu
Journal: Biochem J Date: 1983-02-15 Impact factor: 3.857